To evaluate lotilaner treatment in patients with ocular rosacea.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 18 years of age or older at the time of consent.
* Has moderate to severe ocular rosacea
* Use of acceptable methods of contraception
* Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol
Exclusion Criteria:
* Patient taking a topical or other therapy which may affect the patients rosacea
* Actively managed glaucoma or active ocular infection or ocular systemic disease
* Have hypersensitivity to lotilaner or any of the formulation components
* Are currently enrolled in an investigational drug or device study
* Are currently pregnant or lactating or planning to become pregnant during the study
Primary outcome measure(s)
Incidence of Treatment Emergent Adverse Events — Week 16 Number of patients with treatment related emergent adverse events (TEAEs)
Trial sites (2)
Facility
City
Region
Status
Site
Houston
Texas
Site
Lynchburg
Virginia
More Tarsus Pharmaceuticals, Inc. trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.